Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjectss

Drug Metabolism and Disposition

Volumn 41, Issue 2, 2013, Pages 445-456

  Miao, Zhuang ^a   Nucci, Gianluca ^c   Amin, Neeta ^b   Sharma, Raman ^a   Mascitti, Vincent ^a   Tugnait, Meera ^a   Vaz, Alfin D ^a   Callegari, Ernesto ^a   Kalgutkar, Amit S ^a  

^a PFIZER INC   (United States)

^b Cardiovascular Metabolic and Endocrine Diseases Research Unit   (United States)

^c Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O BETA GLUCURONIDE; 4 O BETA GLUCURONIDE; CARBON 14; CYTOCHROME P450; DESETHYLERTUGLIFLOZIN; DRUG METABOLITE; ERTUGLIFLOZIN; GLUCOSIDE; GLUCURONIDE; HYDROXYL GROUP; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENZYME ACTIVITY; FECES ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; GLUCURONIDES; HUMANS; HYDROXYLATION; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; SODIUM-GLUCOSE TRANSPORTER 2; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84872733237     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049551     Document Type: Article

References (34)

1. Abdul-Ghani MA and DeFronzo RA (2008) Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 14:782-790.
2. Adachi T, Yasuda K, and Okamoto Y, et al. (2000) T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 49:990-995. (Pubitemid 30641434)
3. Bailey CJ, Gross JL, Pieters A, Bastien A, and List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223-2233.
4. Boldys A and Okopien B (2009) Inhibitors of type 2 sodium glucose co-transporters - a new strategy for diabetes treatment. Pharmacol Rep 61:778-784.
5. DeFronzo RA (1988) Lilly lecture 1987. The triumvirate: b-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687. (Pubitemid 19043172)
6. Defronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795.
7. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, and Isaji M (2008) Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 327:268-276.
8. Ghosh RK, Ghosh SM, Chawla S, and Jasdanwala SA (2012) SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol 52:457-463.
9. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, and Eickelmann P (2012) Empagliflozin, a novel selective sodium glucose cotransporter- 2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14:83-90.
10. Hamilton RA, Garnett WR, and Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413. (Pubitemid 11134120)
11. Hussey EK, Clark RV, Amin DM, Kipnes MS, O'Connor-Semmes RL, O'Driscoll EC, Leong J, Murray SC, Dobbins RL, and Layko D, et al. (2010) Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 50: 623-635.
12. Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, and Boulton DW (2011b) Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 13:357-365.
13. Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, and Boulton DW (2011a) Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther 33:1798-1808.
14. Kalgutkar AS, Tugnait M, Zhu T, Kimoto E, Miao Z, Mascitti V, Yang X, Tan B, Walsky RL, and Chupka J, et al. (2011) Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos 39:1609-1619.
15. Kanai Y, Lee WS, You G, Brown D, and Hediger MA (1994) The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397-404.
16. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, and Isaji M (2007) Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 320:323-330. (Pubitemid 46025747)
17. Mascitti V (2011) "Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives" PCT Int. Appl. WO2011051864, 2011. Chem Abstr 154:540739.
18. Mascitti V, Maurer TS, Robinson RP, Bian J, Boustany-Kari CM, Brandt T, Collman BM, Kalgutkar AS, Klenotic MK, and Leininger MT, et al. (2011) Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem 54:2952-2960.
19. Mascitti V, Thuma BA, Smith AC, Robinson RP, Brandt T, Kalgutkar AS, Maurer TS, Samas B, and Sharma R (2013) On the importance of synthetic organic chemistry in drug discovery: reflections on the discovery of antidiabetic agent PF-04971729. MedChemComm, DOI: 10. C2MD20163A.
20. Nair S and Wilding JP (2010) Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 95:34-42.
21. Neumiller JJ, White JR, Jr., and Campbell RK (2010) Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 70:377-385.
22. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, and Anai M, et al. (1999) T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48:1794-1800. (Pubitemid 29415199)
23. Pajor AM and Wright EM (1992) Cloning and functional expression of a mammalian Na+ /nucleoside cotransporter. A member of the SGLT family. J Biol Chem 267:3557-3560.
24. Patel AK and Fonseca V (2010) Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors. Curr Diab Rep 10:101-107.
25. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, and Rothenberg P (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13:669-672.
26. Shah NK, Deeb WE, Choksi R, and Epstein BJ (2012) Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 32:80-94.
27. Sigafoos JF, Bowers GD, Castellino S, Culp AG, Wagner DS, Reese MJ, Humphreys JE, Hussey EK, O'Connor Semmes RL, and Kapur A, et al. (2012) Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. Drug Metab Dispos 40:2090-2101.
28. Wallner EI, Wada J, Tramonti G, Lin S, and Kanwar YS (2001) Status of glucose transporters in the mammalian kidney and renal development. Ren Fail 23:301-310. (Pubitemid 32692267)
29. Wang L, Zhang D, Swaminathan A, Xue Y, Cheng PT, Wu S, Mosqueda-Garcia R, Aurang C, Everett DW, and Humphreys WG (2006) Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection. Drug Metab Dispos 34:427-439. (Pubitemid 43290901)
30. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, and Fiedorek FT (2009) A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32:1656-1662.
31. Wright EM (2001) Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 280: F10-F18.
32. Wright EM and Turk E (2004) The sodium/glucose cotransport family SLC5. Pflugers Arch 447: 510-518. (Pubitemid 38241437)
33. Zhang X, Urbanski M, Patel M, Zeck RE, Cox GG, Bian H, Conway BR, Pat Beavers M, Rybczynski PJ, and Demarest KT (2005) Heteroaryl-O-glucosides as novel sodium glucose cotransporter 2 inhibitors. Part 1. Bioorg Med Chem Lett 15:5202-5206. (Pubitemid 41463647)
34. Zhang D, Wang L, Raghavan N, Zhang H, Li W, Cheng PT, Yao M, Zhang L, Zhu M, and Bonacorsi S, et al. (2007) Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. Drug Metab Dispos 35:150-167. (Pubitemid 46036488)